Pfizer inc
PFE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上
PFE 近期報酬表現
-0.19%
Pfizer inc
0.98%
同產業平均
0.02%
S&P500
與 PFE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
LLY | Eli lilly and company | 4 分 | 3 分 | 4 分 | 3 分 | 5 分 | |
NVS | Novartis ag | 3 分 | 3 分 | 2 分 | 2 分 | 5 分 | |
BMY | Bristol-myers squibb company | 4 分 | 2 分 | 2 分 | 2 分 | 5 分 | |
JNJ | Johnson & johnson | 2 分 | 2 分 | 1 分 | 3 分 | 5 分 | |
GILD | Gilead sciences, inc. | 4 分 | 1 分 | 1 分 | 3 分 | 4 分 |
- LLY Eli lilly and company價值 4 分趨勢 3 分波段 4 分籌碼 3 分股利 5 分查看更多
PFE 公司資訊
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.